Table 1 Summary of BRAF inhibitor trials
From: Therapy for metastatic melanoma: the past, present, and future
Trial | Patients | RR% | PFS (months) | OS (years) | Number (Patients) | Summary |
|---|---|---|---|---|---|---|
Phase 2 Ribas et al. [15] | Vemurafenib in previously treated metastatic melanoma | 52 | 6.2 | Not yet reached | 132 | Met primary end point of best overall survival target of 30% (95% CI: 43 to 61%) |
Phase 3 Chapman et al. [16] | Vemurafenib versus dacarbazine in untreated metastatic melanoma | 48 v 5 | 5.3 v 1.6 | Not yet reached | 675 | Compared vemurafenib and dacarbazine with co-primary endpoints of overall survival and progression free survival. 84% vs 64% OS at 6 months (95% CI: 78 to 89) |